

The performance of prognostic models as predictors of mortality in patients with acute decompensation of cirrhosis

Leonardo Fayad,* Janaína Luz Narciso-Schiavon,* César Lazzarotto,* Marcelo Fernando Ronsoni,* Letícia Muraro Wildner,** Maria Luiza Bazzo,** Leonardo de Lucca Schiavon,* Esther Buzaglo Dantas-Corrêa*

* Department of Internal Medicine, Division of Gastroenterology, ** Department of Clinical Analysis, Federal University of Santa Catarina (UFSC), Brazil.

ABSTRACT

Background. Although several prognostic models have been proposed for cirrhotic patients listed for transplantation, the performance of these scores as predictors of mortality in patients admitted for acute decompensation of cirrhosis has not been satisfactorily investigated. **Aims.** To study MELD, MELD-Na, MESO, iMELD, Refit-MELD and Refit MELD-Na models as prognostic predictors in cirrhotic patients admitted for acute decompensation, and to compare their performance between admission and 48 hours of hospitalization to predict in-hospital mortality. **Material and methods.** This cohort study included cirrhotic patients admitted to hospital due to complications of the disease. Individuals were evaluated on admission and after 48 h of hospitalization, and mortality was evaluated during the present admission. **Results.** One hundred and twenty-three subjects with a mean age of 54.26 ± 10.79 years were included; 76.4% were male. Mean MELD score was 16.43 ± 7.08 and 52.0% of patients were Child-Pugh C. Twenty-seven patients (22.0%) died during hospitalization. Similar areas under the curve (AUROCs) for prognosis of mortality were observed when different models were compared on admission ($P > 0.05$) and after 48 h of hospitalization ($P > 0.05$). When models executed after 48 h of hospitalization were compared to their corresponding model calculated on admission, significantly higher AUROCs were obtained for all models ($P < 0.05$), except for MELD-Na ($P = 0.075$) and iMELD ($P = 0.119$). **Conclusion.** The studied models showed similar accuracy as predictors of in-hospital mortality in cirrhotic patients admitted for acute decompensation. However, the performance of these models was significantly better when applied 48 h after admission when compared to their calculation on admission.

Key words. Liver cirrhosis. Mortality. Survival. Prognosis. MELD.

BACKGROUND

Liver fibrosis stage is probably the most robust prognostic factor in several liver diseases.¹ Cirrhosis is the end-stage of every chronic liver disease.² Its natural history is characterized by an asymptomatic phase, named “compensated cirrhosis”, and followed by the development of complications of portal hypertension and/or liver dysfunction,

named “decompensated cirrhosis”.³ Decompensated cirrhosis is defined by the presence of ascites, variceal bleeding, encephalopathy, and/or jaundice.⁴ Transition from a compensated to a decompensated stage occurs at a rate of approximately 11% per year.⁵ Ten years after diagnosis, the probability of developing decompensated cirrhosis is 58%, whereas ascites is the most frequent complication (47%).⁶ Once patients have developed the first episode of decompensation, life expectancy is markedly reduced.⁷ The course of cirrhosis is extremely variable from patient to patient due to several factors. Hence, it is very difficult to define prognosis in individuals with end-stage liver disease.⁸

Traditionally, prognosis of cirrhosis has been determined by the Child-Turcotte-Pugh (CTP) and/or Model for End-Stage Liver Disease (MELD) scoring systems, despite the fact that they were initially validated for assessing survival

Correspondence and reprint request: Janaína Luz Narciso-Schiavon, MD, PhD.
Departamento de Clínica Médica. Hospital Universitário Polydoro Ernani de São Thiago (UFSC), 3º andar.
Rua Professora Maria Flora Pausewang s/nº, Trindade, Florianópolis-SC, 88040-900, Brazil.
Phone: (+55 48) 37219149. Fax: (+55 48) 37219014.
E-mail: janaina.narciso@uol.com.br

Manuscript received: February 28, 2014.
Manuscript accepted: August 8, 2014.

in patients undergoing surgery for portal hypertension and transjugular intrahepatic portosystemic shunts, respectively.⁹⁻¹¹ The name "Child-Pugh" refers to a currently applied modified score system from the original CTP.¹² Many known limitations of the Child-Pugh score exist, including the reliance on subjective interpretation of qualitative variables and the empirical choice of the five variables.¹³

MELD score is based on bilirubin, international normalized ratio (INR) and creatinine. The three variables were selected based on statistical analysis rather than by empirical means, as with the Child-Pugh score.¹⁴ MELD score became a reliable marker of early mortality and has been adopted for organ allocation to patients listed for liver transplantation in the United States since 2002 and in Brazil since 2006.¹⁴⁻¹⁶

The MELD score-Na (MELD-Na) incorporated serum sodium (SNa) into the equation by adding additional scores to the original MELD in patients with SNa between 120 mEq/L and 134 mEq/L. Recent studies have shown that the incorporation of SNa to MELD calculations can improve the prediction of short-term mortality in patients with cirrhosis.¹⁷⁻²⁰

Posteriorly, further studies also assessed the prognosis of cirrhotic patients with MELD-based models, such as iMELD (integrated MELD) and MESO index (MELD to sodium index), and likewise, both scores included the SNa within their equations to improve their prognostic power.^{21,22} Additional modifications of the MELD score were proposed for optimization of the model.²³ These versions, called Refit MELD and Refit MELDNa, incorporate coefficients and restore lower and upper bounds for the variables MELD and MELD-Na, respectively. Refit MELD and Refit MELDNa have been shown to be more efficient than the original model as prognostic predictors in patients listed for liver transplantation.²³

Although several prognostic models have been proposed for cirrhotic patients on the transplantation list, the performance of these scores as predictors of mortality in patients admitted for acute decompensation of cirrhosis has not been satisfactorily investigated. The aim of this study was to evaluate the models MELD, MELD-Na, MESO, iMELD, Refit MELD, and Refit MELD-Na as prognostic predictors of in-hospital mortality in cirrhotic patients admitted for acute decompensation, and to compare their performance on admission and 48 h after admission.

MATERIAL AND METHODS

Patients

This cohort study included consecutive patients admitted to the emergency department of a tertiary Brazilian hospital for acute decompensation of liver cirrhosis. Acute decompensation was defined by the acute development of hepatic encephalopathy, large ascites, gastrointestinal bleeding, bacterial infection, or any combination of these. Exclusion criteria from this study included the following: individuals admitted for elective procedures, admissions unrelated to liver cirrhosis complications or those that lasted less than 48 h, absence of laboratory tests for calculating the prognostic models at admission and/or 48 h after, and refusal from patient or caregiver or inability to understand the terms of the informed consent. If a patient was admitted more than once during the study period, only the most recent was considered.

Diagnosis of cirrhosis was established histologically (when possible), or clinically by combining imaging, clinical, and laboratorial findings, as well as evidence of portal hypertension.

The study protocol was approved by the Ethics Committee on Human Research of the Federal University of Santa Catarina (UFSC).

Procedures

Individuals with suspected infection at hospital admission were submitted to clinical examination to confirm this diagnosis and to establish the primary source of infection. A diagnostic paracentesis was performed in all patients with ascites at admission. Spontaneous bacterial peritonitis (SBP) was diagnosed when the neutrophil count of the ascitic fluid was ≥ 250 neutrophils/mm³ in the absence of intra-abdominal source of infection, regardless of negative culture.²⁴ All patients with SBP received ceftriaxone plus weight-based intravenous albumin in the first and third day after the diagnosis. Hepatic encephalopathy was graded according to the West-Haven criteria (and, if present, a precipitant event was actively investigated, lactulose was initiated, and the dose adjusted as needed).²⁵ All subjects with acute variceal bleeding received intravenous octreotide and an antibiotic (oral norfloxacin or an intravenous option, ciprofloxacin or ceftriaxone) and underwent urgent therapeutic endoscopy after stabilization. Esophageal varices were treated with band ligation whenever technically feasible or with sclerotherapy in the remaining cases. Secondary prophylaxis with

propranolol (if not contra-indicated) was started on the 6th day of hospitalization, and the patients were scheduled for follow-up endoscopies with band ligation.²⁶ All patients were initially admitted in the emergency room. The decision to transfer the patient to the ward or the intensive care unit (ICU) was made at the discretion of the attending physician according to the severity of the acute decompensation.

Patients were evaluated within the first 12 h of admission by one of the involved researchers, and the following clinical variables were collected: age, gender, etiology of cirrhosis, and current and previous decompensation. Current alcoholism was defined as an average consumption of 21 or more alcoholic drinks per week for men and 14 or more alcoholic drinks per week for women during 4 weeks prior to inclusion in the study (a standard dose of alcohol is equivalent to 12 g of absolute alcohol).²⁷ All patients underwent laboratory evaluation within 12 h of hospital admission and 48 h after admission, and the following variables were considered for the study: creatinine, sodium, total bilirubin and INR. Patients were observed during hospitalization for definition of the studied outcome (in-hospital mortality). CTP classification was used for characterization of the patients.²⁸

Prognostic models

The following prognostic models were calculated based on tests performed on admission and 48 h after admission: MELD,²⁹ MELD-Na,³⁰ MESO,²¹ iMELD,²² Refit MELD, and Refit MELD-Na.²³ See annex 1 for calculation formula of prognostic models.

Statistical analysis

Kolmogorov-Smirnov Testing was performed to evaluate the normality of the distribution of each variable. Continuous variables were compared using the Student's "t" test, for normal distributions, or Mann-Whitney, for the remaining cases. Categorical variables were evaluated using a chi-square or Fisher's exact test as needed. The accuracy of prognostic models was analyzed by receiver operating characteristics (ROC) curves and by calculating the sensitivity, specificity, and positive and negative predictive values for the chosen cutoffs. Comparisons of ROC curves were performed by MedCalc software version 12.4 (MedCalc Software, Mariakerke, Belgium) by the technique described by Hanley & McNeil.³¹ Calibration of the models was assessed by

the Hosmer-Lemeshow goodness-of-fit test. All the remaining tests were two-tailed and were performed by the statistical software SPSS, version 17.0 (SPSS, Chicago, IL, USA). *P*-Values of less than 0.05 were considered statistically significant.

RESULTS

Patient characteristics

From December 2010 to November 2012, 199 admissions for acute decompensation of liver cirrhosis were performed. However, some patients had more than one hospitalization during the study period and, in this case, only the most recent admission was considered. Though, 140 patients were evaluated for inclusion. Thirteen patients who remained hospitalized for less than 48 h were excluded. Also, an additional four individuals were excluded due to absence of laboratory tests. Thus, 123 patients were eligible for the study (Figure 1).

The included patients had a mean age of 54.26 ± 10.79 years, and were mostly male (76.4%) and Caucasian (56.9%). Current alcohol consumption was reported by 42.3% of patients. The main causes of liver cirrhosis were hepatitis C virus and alcohol in 50 (40.7%) and 49 (39.8%) patients, respectively. Previous episodes of decompensated liver disease was reported by 79 patients (64.2%), and 52.0% were classified as Child-Pugh C.




Figure 1. Flow diagram of the potential candidates for participation in the study, reason for exclusions, and subjects enrolled.

Table 1. Characteristics of 123 individuals admitted for acute decompensation of liver cirrhosis.

	All (n = 123)	Surviving (n = 96)	Dead (n = 27)	P
Mean age (years)	54.26	53.53	52.30	0.601
± SD	± 10.79	± 10.94	± 10.39	
Male, n (%)	94 (76.4%)	73 (76.0%)	21 (77.8%)	0.851
Cause of cirrhosis, n (%)				
HCV	50 (40.7%)	39 (40.6%)	11 (40.7%)	0.991
HBV	4 (3.3%)	4 (4.2%)	0 (0%)	0.575
Alcohol	49 (39.8%)	35 (36.5%)	14 (51.9%)	0.149
Cryptogenic	7 (5.7%)	7 (7.3%)	0 (0%)	0.346
Other	13 (10.6%)	11 (11.5%)	2 (7.4%)	0.731
First decompensation, n (%)	44 (35.8%)	34 (35.4%)	10 (37.0%)	0.877
Current alcoholism, n (%)	52 (42.3%)	37 (38.5%)	15 (55.6%)	0.114
Current ascites, n (%)	64 (52.0%)	40 (41.7%)	24 (88.9%)	< 0.001
Gastrointestinal bleeding, n (%)	70 (56.9%)	58 (60.4%)	12 (44.4%)	0.139
Hepatic encephalopathy, n (%)	77 (62.6%)	55 (57.3%)	22 (81.5%)	0.022
SBP, n (%)	19 (15.4%)	10 (10.4%)	9 (33.3%)	0.007
Other infections, n (%)	21 (17.1%)	13 (13.5%)	8 (29.6%)	0.079
Creatinine (mg/dL), median	1.10	1.00	1.50	< 0.001
Sodium (mEq/L), median	136.00	136.00	134.00	0.208
INR, median	1.40	1.38	1.57	0.023
Total bilirubin (mg/dL), median	1.70	1.40	2.70	0.019
CTP Classification, n (%)				
A	15 (12.2%)	15 (15.6%)	0 (0%)	0.040
B	44 (35.8%)	39 (40.6%)	5 (18.5%)	0.034
C	64 (52.0%)	42 (43.8%)	22 (81.5%)	0.001

SD: standard deviation. HCV: hepatitis C virus. HBV: hepatitis B virus. SBP: spontaneous bacterial peritonitis. mg/dL: milligrams per deciliter. mEq/L: milliequivalents per liter. INR: international normalized ratio. CTP: child-turcotte-pugh.

Upon admission, present complications included ascites (52.0%), upper gastrointestinal bleeding (56.9%), and hepatic encephalopathy (62.6%). Regarding infections, SBP was present in 15.4% of cases, and other infections were present in 17.1% of the sample (Table 1). Renal dysfunction (creatinine levels ≥ 2 mg/dL) was observed in 16.3% of the patients.

Twenty-one patients (17%) were later transferred to the intensive care unit.

Performance of prognostic models in predicting in-hospital mortality

Among individuals included in the study, 27 (22.0%) died during hospitalization. Compared to the others, these individuals had higher proportions of ascites ($P < 0.001$), hepatic encephalopathy ($P = 0.022$) and spontaneous bacterial peritonitis (SBP) ($P = 0.007$) at admission. Moreover, those who died were classified as CTP C more frequently ($P < 0.001$) and had higher creatinine ($P < 0.001$), INR ($P = 0.023$) and bilirubin levels ($P = 0.019$). Also,

a trend was found towards higher rates of other infectious complications among those who died compared to others ($P = 0.079$). No differences were observed for the other variables (Table 1).

Table 2 shows values of the MELD, MELD-Na, MESO, iMELD, Refit MELD, and Refit MELD-Na models at admission and 48 h after admission. Significantly, higher mean values ($P < 0.001$) were observed for all models among individuals who died compared to survivors.

ROC curves of the studied models at admission and 48 h after admission were plotted to evaluate their performance in predicting in-hospital mortality. Upon admission, the values for the area under the ROC curve (AUROC) were 0.785 ± 0.053 (MELD), 0.784 ± 0.052 (MESO), 0.782 ± 0.050 (Refit MELD), 0.781 ± 0.053 (MELD-Na), 0.776 ± 0.052 (Refit MELD-Na), and 0.770 ± 0.053 (iMELD). No significant differences were observed when model equations calculated at admission were compared among each other ($P > 0.05$). The same models were calculated after 48 h of hospitalization and the result-

Table 2. Values of prognostic models accordingly to in-hospital mortality.

	All (n = 123)	Surviving (n = 96)	Dead (n = 27)	P ^t
Admission				
MELD	16.43 ± 7.08	14.73 ± 5.92	22.44 ± 7.70	< 0.001
MELD-Na	19.12 ± 7.38	17.45 ± 6.48	25.06 ± 7.44	< 0.001
MESO	1.23 ± 0.55	1.09 ± 0.47	1.69 ± 0.59	< 0.001
iMELD	38.12 ± 9.22	36.21 ± 8.42	44.90 ± 8.84	< 0.001
ReFit MELD	16.51 ± 6.98	14.93 ± 6.09	22.16 ± 7.11	< 0.001
ReFit MELD-Na	16.67 ± 6.46	15.26 ± 5.83	21.69 ± 6.19	< 0.001
48 hours				
MELD	15.67 ± 7.32	13.25 ± 5.07	24.28 ± 7.64	< 0.001
MELD-Na	17.99 ± 7.37	15.68 ± 5.41	26.21 ± 7.62	< 0.001
MESO	1.16 ± 0.55	0.97 ± 0.37	1.82 ± 0.59	< 0.001
iMELD	36.52 ± 8.71	33.89 ± 6.30	45.88 ± 9.71	< 0.001
ReFit MELD	15.73 ± 7.25	13.44 ± 5.33	23.88 ± 7.38	< 0.001
ReFit MELD-Na	15.79 ± 6.52	13.78 ± 4.89	22.95 ± 6.63	< 0.001

MELD: Model for End-Stage Liver Disease. MELD-Na: MELD with serum sodium incorporation. MESO: model for end stage liver disease to sodium index. iMELD: integrated MELD. Refit MELD: revised model for end-stage liver disease. Refit MELD-Na: revised model for end-stage liver disease with sodium. t: Student's "t" test.

Table 3. Performance of the selected cutoffs and the values for the area under the ROC curve of prognostic models calculated at admission and 48 h after admission in predicting in-hospital mortality.

Model	Cutoff	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	AUROC
Admission						
MELD	17.5	74	77	48	91	0.785 ± 0.053
MELD-Na	22.0	70	79	49	90	0.781 ± 0.053
MESO	1.3	74	78	49	91	0.784 ± 0.052
iMELD	39.0	81	70	43	93	0.770 ± 0.053
Refit MELD	18.0	74	78	49	91	0.782 ± 0.050
Refit MELD-Na	17.0	78	72	44	92	0.776 ± 0.052
48 hours						
MELD	19.5	77	91	70	94	0.882 ± 0.039
MELD-Na	23.0	74	90	67	92	0.858 ± 0.049
MESO	1.5	74	93	74	93	0.880 ± 0.041
iMELD	40.0	78	86	62	93	0.842 ± 0.052
Refit MELD	19.5	78	90	68	93	0.876 ± 0.040
Refit MELD-Na	20.0	74	91	69	93	0.858 ± 0.048

PPV: positive predictive value. NPV: negative predictive value. AUROC: area under the ROC curve- MELD: Model for End-Stage Liver Disease. MELD-Na: MELD with sodium. MESO: Model for End-Stage liver Disease to sodium index. iMELD: integrated MELD. Refit MELD: revised model for end-stage liver disease. Refit MELD-Na: revised model for end-stage liver disease with sodium.

ing AUROC values were 0.882 ± 0.039 (MELD), 0.880 ± 0.041 (MESO), 0.876 ± 0.040 (Refit MELD), 0.858 ± 0.048 (Refit MELD-Na), 0.858 ± 0.049 (MELD-Na), and 0.842 ± 0.052 (iMELD). Again, no differences were observed when comparing the models calculated after 48 h of admission ($P > 0.05$). However, when admission models were compared to models calculated 48 h after admission, significantly higher AUROC values were observed for MELD-48

vs. MELD-admission ($P = 0.015$), MESO-48 against MESO-ADM (0.015), Refit-MELD-48 against Refit-MELD-ADM ($P = 0.011$), and Refit-MELD-Na-48 against Refit MELD-Na-admission ($P = 0.049$). A trend was observed towards greater AUROC values for the MELD-Na-48 model compared with MELD-Na-admission ($P = 0.075$). No statistical differences were observed when comparing iMELD-48 model against iMELD-admission ($P = 0.119$).

Based on the ROC curve, best cutoff points were chosen for studied models at admission and 48 h after admission (Table 3). Generally, similar sensitivity was noted at the two moments of model calculation; however, a significant gain in specificity and positive predictive value (PPV) was observed at the 48 h evaluation. Upon admission, very similar performances were observed in many of the models; however, the MELD-Na model showed lower sensitivity (70%) and the iMELD and Refit-MELD-Na models showed lower specificity (70 and 72%, respectively) when compared to the remaining models. The models at 48 h after admission all presented similar performance, except for iMELD, which showed slightly lower specificity than the rest (86%).

In patients admitted for the first episode of hepatic decompensation, the models evaluated after 48 h performed only slightly better than the admission evaluation, without statistical significance ($P > 0.05$). However, in patients having a history of previous decompensation, a significantly better performance was noted for models calculated at 48 h as compared to their counterparts calculated at admission ($P < 0.05$ for all models except MESO, which reached a P -value of 0.094). The AUROCs observed for admission models in those patients were 0.741 ± 0.068 (MELD), 0.745 ± 0.067 (MESO), 0.733 ± 0.066 (Refit MELD), 0.738 ± 0.069 (MELD-Na), 0.734 ± 0.066 (Refit MELD-Na), and 0.721 ± 0.071 (iMELD). The AUROCs for the models at 48 h were 0.874 ± 0.047 (MELD), 0.871 ± 0.049 (MESO), 0.869 ± 0.047 (Refit MELD), 0.841 ± 0.066 (MELD-Na), 0.849 ± 0.059 (Refit MELD-Na), and 0.818 ± 0.068 (iMELD).

The P -values for the Hosmer-Lemeshow goodness-of-fit test for the models at admission were: MELD = 0.441, MELD-Na = 0.367, MESO = 0.271, iMELD = 0.247, Refit-MELD = 0.631, Refit-MELD-Na = 0.366. Similar values were observed after 48 h, with the following P -values: MELD = 0.873, MELD-Na = 0.172, MESO = 0.257, iMELD = 0.594, Refit-MELD = 0.655, Refit-MELD-Na = 0.766. These results indicate adequate calibration of the models at both moments.

DISCUSSION

The determination of prognosis is an essential part in the initial evaluation of any disease. Prognosis is not only the basis for the information that a physician provides to the patient, but also guides clinical approach. Identification of prognostic markers of poor outcome in cirrhotic patients admitted

for acute decompensation could allow better risk stratification, and eventually guide the most appropriate therapeutic measures for each case.

The models MELD-Na, MESO, iMELD, Refit MELD, and Refit MELD-Na incorporate to MELD score coefficients and lower and upper limits of individual variables that have been optimized for the patients for which the MELD score is applied. Most of these models assess waiting-list mortality and thus are the most efficient donated organ allocation classification.

Lee, *et al.* remark that an important issue, perhaps requiring further attention, is that the MELD system was originally created in patients who did not have acute or reversible complications. Whether the MELD system and its derived models can be equally applied as a tool for outcome prediction in different clinical scenarios beyond their original aim requires additional study.³² In contrast to the majority of published studies on this subject, the current work was conducted by evaluation of in-hospital mortality. The present study has compared MELD score to five different prognostic scales (MELD-Na, iMELD, MESO, MELD-Refit, and Refit-MELD-Na), both in admission and after 48 h of hospitalization, to assess in-hospital (short-term) mortality in patients with acute decompensation of liver cirrhosis. Most studies intend to evaluate mid-term and long-term mortality.

In 2009, Didier Samuel recognized the importance of improving prognostic scoring systems for cirrhotic patients. He stressed that applying the new scores to a variety of cirrhotic patients and to different etiologies of the disease is vital, as well as determining the prognostic value of the scores in the short, medium, and longer terms.⁽³³⁾ Before the publication of Refit models,¹⁸ many studies have compared MELD to the new MELD-based models in combination with SNa. Most studies found that new models with the addition of SNa were superior to traditional MELD scores in predicting short, medium, and long term mortality.^{16,17,34-36}

Kim, *et al.* evaluated data from 13,940 patients from the U.S. Standard Transplant Analysis and Research, and concluded that assignment of priority according to the MELD score combined with the SNa concentration might have resulted in transplantation and prevented death.¹⁷ In Southern Brazil, Marroni, *et al.* evaluated 558 individuals on the waiting list for liver transplantation, and they observed that SNa-modified MELD scores are able to more accurately predict 3- and 6-month mortality ($P < 0.001$).¹⁶

Table 4. Characteristics of different studies that evaluated MELD and MELD-based models to predict mortality.

Authors	N. subjects	Sample	Endpoint	Age (years)	MELD	Child C	Serum sodium (mmol/L)	Hypona-tremia	Ascites	Mortality	MELD AUROC	MELD-Na AUROC
Fayad, <i>et al.</i> ¹⁵	123	Decompensated cirrhosis Emergency room	In-hospital mortality	54.26 ± 10.79*	16.43 ± 7.08*	52%	135.0 ± 4.7*	44%	52%	22%	0.882	0.858
Marroni, <i>et al.</i> ¹⁶	558	Transplant list Data bank		53.5 ± 9.5*	15.7 ± 5.5*	N/A	137 ± 5.7*	12%	N/A	33%	0.736/6 m	N/A
Kim, <i>et al.</i> ¹⁷	13,940	Transplant list Data bank	3 m mortality on the waiting list.	53 (18-83) [‡]	15 (6-40) [‡]	N/A	137 [‡] (112-168)	31%	N/A	3%	0.883	0.868
Hassan, <i>et al.</i> ³⁴	1,000	Decompensated cirrhosis In Hospital	12 m mortality	54.8 ± 8*	16.6 ± 5.9*	73%	134 ± 75.5*	25%	74%	11%	0.725	0.743
Hsu, <i>et al.</i> ³⁵	182	Acute decompensated hepatitis	3 m mortality	48 ± 13*	16.8±6.3*	-	137.4 ± 3.5*	N/A	8%	11%	0.823	0.908
LV, <i>et al.</i> ³⁶	256	In Hospital Decompensated cirrhosis In Hospital	1 and 3 months mortality	54.3 ± 11.5*	15.1 ± 6.3*	41%	134.3 ± 7.8*	32%	43%	10%/1 m [§]	0.819/1 m	N/A
Jiang, <i>et al.</i> ³⁷	166	Decompensated cirrhosis In Hospital	3, 6 and 12 m mortality	62.3 ± 12.9*	N/A	N/A	N/A	N/A	N/A	23%/3 m 45%/12 m	N/A	N/A
Zhang, <i>et al.</i> ³⁸	435	Liver cirrhosis N/A	6 and 12 m mortality	N/A	N/A	N/A	N/A	N/A	N/A	25%/6 m 35%/12 m	N/A	N/A
Koo, <i>et al.</i> ³⁹	882	Liver cirrhosis In hospital	3 m mortality	57.5 ± 10.9	16.3 ± 7.3*	28%	N/A	N/A	N/A	9%	0.844	0.848

N/A: not available. AUROC: area under the curve. † median (variation). *mean ± standard deviation. ‡ MELD ≤ 17. §§ MELD > 17. m: months.

The majority of the studies that evaluate the ability of MELD and its derivatives to predict mortality in cirrhotic patients are retrospective, and aim to evaluate 1-, 3-, 6- or 12-month mortality (Table 4).^{34,37-39} As far as we are concerned, this is the first study to evaluate in-hospital mortality.

Very few studies have assessed prognosis of decompensated cirrhosis in the emergency room. Orloff, *et al.* evaluated 211 unselected consecutive patients with cirrhosis and bleeding varices to endoscopic sclerotherapy or emergency portacaval shunt. In baseline determinations of MELD versus Child-Pugh, there were no significant differences in predicting survival, recurrent encephalopathy, and rebleeding. The Child-Turcotte score was significantly more effective in predicting survival and time to recurrent encephalopathy.⁴⁰

No significant differences were observed among the employed scores upon admission and 48 h after admission. We suppose that the similarity encountered among different prognostic models may reflect the finding that admission SNa was not related to mortality in the bivariate analysis and the high proportion of individuals decompensated with hyponatremia. In our series, the median SNa was 135.0 ± 4.7 mEq/mL, 44% of the individuals evidenced hyponatremia, and ascites was present in 52% of the sample. Other studies report a mean SNa level of 134-137 mEq/mL,^{16,17,34-36} with lower proportions of hyponatremia, varying from 12% to 32%.^{16,17,34,36} Cirrhotic patients often exhibit dilutional hyponatremia because of portal hypertension and vasodilatation.⁴¹ Remarkably, hyponatremia is commonly associated with severe complications in liver cirrhosis, including ascites, hepatorenal syndrome and liver related mortality.⁴²⁻⁴⁵ Previous studies have shown that hyponatremia is a strong predictor of early mortality, independent of MELD score.^{19,30,46} The majority (90%) of patients with hyponatremia has a history of ascites,³⁰ and ascites is also a predictor of mortality.⁴⁷ In the present study, when individuals with hyponatremia were compared to those with normal SNa levels, we observed a higher proportion of individuals with ascites among those with hyponatremia (52 *vs.* 25%, $P = 0.002$; data not shown).

In the present study, higher AUROCs were observed within 48 h after hospital admission to predict in-hospital mortality when compared to models upon admission. This was the first study assessing this issue. Patients who respond to initial medical management are probably those with better prognosis, which is more clearly evidenced after 48 h of ad-

mission. Therefore, the MELD score and its derivatives more precisely represent the current liver function status after treating the acute complications that develop in these patients. Higher values of MELD in patients with fatal outcomes were observed in those who developed ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, and those who presented higher values of creatinine, bilirubin, or INR. The MELD score and its derivatives correlate with residual liver function. They have demonstrated the ability to predict mortality in a broad spectrum of liver diseases. The variation in MELD values over time may correspond to dynamic changes in liver function and its increase may predict liver decompensation, especially in those with onset of hepatic encephalopathy or ascites. The determination of MELD score at two moments provides updated information on the severity of the disease and allows more aggressive therapy. On the other hand, the decrease in serial MELD values could indicate the correction of a reversible element, therefore reflecting a lower risk of mortality. Thus, the MELD score analysis in two different periods of time transmits additional clinical information and should be considered as a predictive factor in patients admitted for decompensated cirrhosis.

We acknowledge some limitations to our analysis. The primary and most obvious shortcoming of single-center studies is their potentially limited external validity, although they allow larger, multicenter studies to be planned appropriately and powered. This study was conducted in a referral center for liver transplantation and the studied sample is comparable to other populations in the world. Secondly, MELD-derived systems exclusively rely on objective laboratory data, and variations in laboratory methods potentially affect its accuracy. For instance, diuretics could influence creatinine levels. Despite their drawbacks, MELD-derived systems have been extensively used as a prognostic marker in cirrhosis. In the present study, all laboratory data were performed in the same institution. Additionally, the determination of the MELD-based equations on admission could eliminate possible bias such as diuretics treatment which could possibly alter creatinine and SNa level and confound the calculation of the scores. And finally, the relatively small number of patients included could limit the interpretation of the results. However, the prospective data collection and initial evaluation in the emergency room give the study elements that reflect the reality of clinical practice.

CONCLUSION

MELD-based models showed similar accuracy as predictors of mortality in cirrhotic patients admitted for acute decompensation. However, the performance of these models was significantly better when applied 48 h after hospitalization when compared to their calculation on admission especially in patients with history of previous hepatic decompensation.

ABBREVIATIONS

- **CTP:** Child-Turcotte-Pugh.
- **iMELD:** integrated MELD.
- **MELD:** Model for End-Stage Liver Disease.
- **MESO index:** MELD to sodium index.
- **Refit MELD:** Revised Model for End-Stage Liver Disease.
- **SNa:** serum sodium.

REFERENCES

1. Schiavon L de L, Narciso-Schiavon JL, de Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. *World J Gastroenterol* 2014; 20: 2854-66.
2. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. *J Clin Pathol* 1978; 31: 395-414.
3. D'Amico G, Garcia-Tsao G, Cales P, Escorsell A, Nevens F, Cestari R, Caletti G, et al. Session 2 Diagnosis of Portal Hypertension: How and When. In: Portal Hypertension III: Proceedings of the Third Bavero International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies: Blackwell Science Ltd; 2008, 36-64.
4. Saunders JB, Walters JR, Davies AP, Paton A. A 20-year prospective study of cirrhosis. *Br Med J (Clin Res Ed)* 1981; 282: 263-6.
5. Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. *Aliment Pharmacol Ther* 2010; 32: 1343-50.
6. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, Caballeria J, et al. Compensated cirrhosis: natural history and prognostic factors. *Hepatology* 1987; 7: 122-8.
7. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol* 2006; 44: 217-31.
8. Kim HJ, Lee HW. Important predictor of mortality in patients with end-stage liver disease. *Clin Mol Hepatol* 2013; 19: 105-15.
9. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). *Hepatology* 2007; 45: 797-805.
10. Child CG. Surgery and portal hypertension. In: Child C (ed.). *The Liver and Portal Hypertension*. Philadelphia, PA: WB Saunders; 1964, 50-72.
11. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology* 2000; 31: 864-71.
12. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973; 60: 646-9.
13. Durand F, Valla D. Assessment of prognosis of cirrhosis. *Semin Liver Dis* 2008; 28: 110-22.
14. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology* 2003; 124: 91-6.
15. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. *Liver Transpl* 2004; 10: 7-15.
16. Marroni CP, de Mello Brandao AB, Hennigen AW, Marroni C, Zanotelli ML, Cantisani G, Fuchs SC. MELD scores with incorporation of serum sodium and death prediction in cirrhotic patients on the waiting list for liver transplantation: a single center experience in southern Brazil. *Clin Transplant* 2012; 26: E395-401.
17. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. *N Engl J Med* 2008; 359: 1018-26.
18. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. *Hepatology* 2004; 40: 802-10.
19. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. *Hepatology* 2005; 41: 32-9.
20. Cardenas A, Gines P. Predicting mortality in cirrhosis—serum sodium helps. *N Engl J Med* 2008; 359: 1060-2.
21. Huo TI, Wang YW, Yang YY, Lin HC, Lee PC, Hou MC, Lee FY, et al. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. *Liver Int* 2007; 27: 498-506.
22. Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, Peck-Radosavljevic M, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. *Liver Transpl* 2007; 13: 1174-80.
23. Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. *Gastroenterology* 2011; 140: 1952-60.
24. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. *Hepatology* 2009; 49: 2087-107.
25. Bajaj JS. Review article: the modern management of hepatic encephalopathy. *Aliment Pharmacol Ther* 2010; 31: 537-47.
26. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. *J Hepatol* 2010; 53: 762-8.
27. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. *Lancet* 2007; 370: 1915-22.
28. Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. *Gut* 2003; 52: 879-85.

29. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, et al. A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001; 33: 464-70.
30. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, et al. Evidence-based incorporation of serum sodium concentration into MELD. *Gastroenterology* 2006; 130: 1652-60.
31. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. *Radiology* 1983; 148: 839-43.
32. Lee YH, Hsu CY, Huo TI. Assessing liver dysfunction in cirrhosis: role of the model for end-stage liver disease and its derived systems. *J Chin Med Assoc* 2013; 76: 419-24.
33. Samuel D. MELD-Na as a prognostic score for cirrhotic patients: Hyponatremia and ascites are back in the game. *J Hepatol* 2009; 50: 836-8.
34. Hassan EA, Abd El-Rehim AS. A revised score in different prognostic models in cirrhotic patients: Current and future perspectives, an Egyptian experience. *Arab J Gastroenterol* 2013; 14: 158-64.
35. Hsu CY, Lin HC, Huang YH, Su CW, Lee FY, Huo TI, Lee PC, et al. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. *Dig Liver Dis* 2010; 42: 137-42.
36. Lv XH, Liu HB, Wang Y, Wang BY, Song M, Sun MJ. Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis. *J Gastroenterol Hepatol* 2009; 24: 1547-3.
37. Jiang M, Liu F, Xiong WJ, Zhong L, Chen XM. Comparison of four models for end-stage liver disease in evaluating the prognosis of cirrhosis. *World J Gastroenterol* 2008; 14: 6546-50.
38. Zhang QB, Chen YT, Lian GD, Qian CC, Chen SJ, Huang KH. A combination of models for end-stage liver disease and cirrhosis-related complications to predict the prognosis of liver cirrhosis. *Clin Res Hepatol Gastroenterol* 2012; 36: 583-91.
39. Koo JK, Kim JH, Choi YJ, Lee CI, Yang JH, Yoon HY, Choi HJ, et al. Predictive value of Refit Model for End-Stage Liver Disease, Refit Model for End-Stage Liver Disease-Na, and pre-existing scoring system for 3-month mortality in Korean patients with cirrhosis. *J Gastroenterol Hepatol* 2013; 28: 1209-16.
40. Orloff MJ, Vaida F, Isenberg JI, Wheeler HO, Haynes KS, Jinich-Brook H, Rapier R, et al. Child-Turcotte score versus MELD for prognosis in a randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis. *J Surg Res* 2012; 178: 139-46.
41. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. *Gastroenterology* 1992; 102: 931-5.
42. Borroni G, Maggi A, Sangiovanni A, Cazzaniga M, Salerno F. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. *Dig Liver Dis* 2000; 32: 605-10.
43. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, Navasa M, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. *Gastroenterology* 1993; 105: 229-36.
44. Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. *Hepatology* 2008; 48: 1002-10.
45. Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron-Gonzalez JA. Dilutional hyponatremia in patients with cirrhosis and ascites. *Arch Intern Med* 2002; 162: 323-8.
46. Londono MC, Cardenas A, Guevara M, Quinto L, de Las Heras D, Navasa M, Rimola A, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. *Gut* 2007; 56: 1283-90.
47. Silva PE, Fayad L, Lazzarotto C, Ronsoni MF, Bazzo ML, Colombo BD, Dantas-Correa EB, et al. Single-center validation of the EASL-CLIF Consortium definition of acute-on-chronic liver failure and CLIF-SOFA for prediction of mortality in cirrhosis. *Liver Int* 2014. doi: 10.1111/liv.12597.

Annex 1. Calculation of prognostic models.

MELD	$9.57 \log_e (\text{creatinine [mg/dL]}) + 3.78 \log_e (\text{bilirubin [mg/dL]}) + 11.2 \log_e (\text{INR}) + 6.43$
MELD-Na	$\text{MELD} + 1.59 \times (135 - \text{Na [mmol/L]})$; Na range = 120 and 135 mmol/L
MESO	$(\text{MELD} / \text{Na [mmol/L]}) \times 100$
iMELD	$\text{MELD} + (\text{age [years]} \times 0.3) - (0.7 \times \text{Na [mmol/L]}) + 100$
ReFit MELD	$4.082 \times \text{Log}_e (\text{bilirubin}_c) + 8.485 \times \text{Log}_e (\text{creatinine}_c) + 10.671 \times \text{Log}_e (\text{INR}_c) + 7.432$
ReFit MELD-Na	$4.258 \times \text{Log}_e (\text{bilirubin}_c) + 6.792 \times \text{Log}_e (\text{creatinine}_c) + 8.290 \times \text{Log}_e (\text{INR}_c) + 0.652 \times (140 - \text{Na}_c) - 0.194 \times (140 - \text{Na}_c) \times \text{Bili}_{cc} + 6.327$

MELD: Model for End-Stage Liver Disease. MELD-Na: MELD with serum sodium incorporation. MESO: Model for End-Stage Liver Disease to Sodium Index. iMELD: integrated MELD. Refit MELD: Revised Model for End-Stage Liver Disease. Refit MELD-Na: Revised Model for End-Stage Liver Disease with sodium.